Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Down 5.48%
As of Friday, October 23, Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 5.48%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Milestone Pharmaceuticals Inc. (MIST)
Milestone Pharmaceuticals Inc. MIST
$0.65
-0.05
-7.76%
October 23, 2026 4:00:00 PM
EST
Volume: 1,553,601
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Commentary & Analysis
Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Up 5.38%
As of Tuesday, October 20, Milestone Pharmaceuticals Inc.’s MIST share price has surged by 5.38%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Down 5.02%
As of Friday, October 16, Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 5.02%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Up 6.01%
As of Friday, October 09, Milestone Pharmaceuticals Inc.’s MIST share price has surged by 6.01%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Milestone Pharmaceuticals Inc.’s (MIST) Stock Is Down 5.86%
As of Thursday, October 08, Milestone Pharmaceuticals Inc.’s MIST share price has dipped by 5.86%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | MIST | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $91.3 | $464.0 | 22% |
|
| Shares Out (Mil) | 138.7 | 42.7 | 69% |
|
| Institutional Ownership | 96.8% | 82.2% | 71% |
|
| Float (Mil) | 106.5 | 44.3 | 62% |
|
| Beta | 0.98 | 0.73 | 58% |
|
| Avg Daily Volume (000s) | 915 | 292 | 69% |
|
| Price Change (52-week) |
(66.1%) | 55.0% | 13% |
|
| Growth | MIST | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (4.8%) | (2.4%) | 34% |
|
| EPS (5yr) | 15.1% | 14.9% | 57 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | 18.7% | (15.1%) | 78% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.214) | ($0.842) | ($0.782) | |
| Month Ago EPS | ($0.212) | ($0.838) | ($0.772) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.210) | ($0.830) | ($0.908) | |
| Year/Year Chg | 3.9% | 12.0% | (62.8%) | |
| Financials | MIST | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $416 | 4% |
|
| Net Income (TTM) (Mil) | ($84) | ($11) | 13% |
|
| EPS (TTM) | ($0.712) | ($0.700) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($61) | ($7) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $127 | $5 | 80% |
|
| Long-Term Debt (Q1) (Mil) | $141 | $6 | 47% |
|
| Enterprise Value (Q1) (Mil) | $83 | $493 | 20% |
|
| Valuation | MIST | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.99 | 2.09 | 80% |
|
| P/E | na | 17.3 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | MIST | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 98.0% | 69.4% | 96% |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (73.4%) | (22.2%) | 8% |
|
| ROE | na | (21.0%) | na |
|
| Liabilities to Assets | 90.0% | 32.3% | 86% |
|
| F-Score | 3 | 3 | 18% |
|
Milestone Pharmaceuticals Inc. did not pass any screens on 10/23/2026.
